@article{b74ca929610241079d0a547fdf7bb205,
title = "A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy",
author = "Dy, {Grace K.} and Dheerendra Prasad and Prasanna Kumar and Kristopher Attwood and Adjei, {Alex A.}",
note = "Funding Information: This study was approved and funded by the National Comprehensive Cancer Network Oncology Research Program from the general research support provided by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). BIPI had no role in the design, analysis, or interpretation of the results in this study; BIPI was given the opportunity to review the manuscript for medical and scientific accuracy as it relates to BIPI substances and intellectual property considerations.",
year = "2021",
month = mar,
doi = "10.1016/j.jtho.2020.11.019",
language = "English (US)",
volume = "16",
pages = "e19--e20",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "3",
}